Table 7. NY-ESO-1 Vaccine, Adoptive T Cell Therapy and Combinatorial Immune-Based Interventions Currently in Clinical Trial.
| ID | National clinical trial (NCT) number | Type | Interventions | Conditions | Status |
|---|---|---|---|---|---|
| GCO 14-0780 | NCT02334735 | Vaccines | Multi peptide (NY-ESO-1 and Melan-A/MART-1) - pulsed DC vaccine | Melanoma | Recruiting |
| IMDZ-C131 | NCT02387125 | Vaccines | CMB305 (peptide-pulsed DC vaccine LV305 + G305 recombinant NY-ESO-1 protein vaccine)/TLR4 agonist (G100) | Melanoma | Recruiting |
| ID-LV305-2013-001 | NCT02122861 | Vaccines | DC lentiviral vector vaccine (LV305) | Melanoma | Active, not recruiting |
| NCI-2014-00898/CITN-07- FLT3L/U01CA154967 | NCT02129075 | Vaccines | DEC-205/NY-ESO-1 fusion protein vaccine (CDX-1401) + recombinant Flt3 ligand (CDX-301) | Stage II - IV melanoma | Active, not recruiting |
| ADP 01611 | NCT01350401 | Adoptive T cell therapy | NY-ESO-1c259-T cells | Metastatic melanoma | Active, not recruiting |
| MAT-02/2012-000450-63 | NCT01946373 | Combinatorial immune-based intervention | Peptide-pulsed DC vaccine/TILs | Melanoma | Recruiting |
| MCC-15400/NCI-P-7997/ CA209-006/007/10-15526-99-01 | NCT01176461 | Combinatorial immune-based intervention | Multi peptide vaccine (MART-1, NY-ESO-1, gp100209-217, gp100280-288/PD-1 inhibitor) (nivolumab) | Melanoma | Active, not recruiting |
| MCC-15651/NCI-8316 | NCT01176474 | Combinatorial immune-based intervention | NY-ESO-1157-165/gp100280-288 vaccine/PD-1 inhibitor (nivolumab)/PD-1 inhibitor (nivolumab)/CTLA-4 inhibitor (ipilimumab) | Stage III - IV melanoma | Active, not recruiting |
NY-ESO-1: New York esophageal squamous cell carcinoma 1; DC: dendritic cell; PD-1: programmed cell death protein-1.